about
Histone recognition and large-scale structural analysis of the human bromodomain familyIdentification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived HitBenzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET familyBET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor ModelsTargeting MYC dependence in cancer by inhibiting BET bromodomainsBromodomain Protein BRD4 Is a Transcriptional Repressor of Autophagy and Lysosomal Function.Nuclear Protein in Testis Midline Carcinoma Presenting in an Infant as a Pericardial Mass with Staging by 18F-Fluorodeoxyglucose-positron Emission Tomography/Computed Tomography.Omics-based molecular techniques in oral pathology centred cancer: prospect and challenges in Africa.7,9-Diaryl-1,6,8-trioxaspiro[4.5]dec-3-en-2-ones: readily accessible and highly potent anticancer compounds.SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract.Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammationMechanistic analysis of the role of bromodomain-containing protein 4 (BRD4) in BRD4-NUT oncoprotein-induced transcriptional activation.Cytological Features of a Variant NUT Midline Carcinoma of the Lung Harboring the NSD3-NUT Fusion Gene: A Case Report and Literature Review.NUT rearrangement is uncommon in human thymic epithelial tumorsSubstrate Specificity of the HEMK2 Protein Glutamine Methyltransferase and Identification of Novel SubstratesNUT expression in primary lung tumoursNuclear protein in testis midline carcinoma misdiagnosed as adamantinoma.The role of the double bromodomain-containing BET genes during mammalian spermatogenesis.Brd4 and HEXIM1: multiple roles in P-TEFb regulation and cancer.Progress in the discovery of small-molecule inhibitors of bromodomain--histone interactions.NUT midline carcinoma: an imaging case series and review of literature.NUT midline carcinoma: a case report with a novel translocation and review of the literature.NUT midline carcinomas in the thymic region.The impact of immunohistochemistry on the classification of lung tumors.Cytological features of NUT midline carcinoma arising in sino-nasal tract and parotid gland: Report of two new cases and review of the literature.Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.NUT midline carcinoma of the larynx: an international series and review of the literature.Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.Targeting Cancer Cells with BET Bromodomain Inhibitors.Utility of p40 in the Differential Diagnosis of Small Round Blue Cell Tumors of the Sinonasal TractUltrastructural features of NUT midline carcinoma.Small round blue cell tumors of the sinonasal tract: a differential diagnosis approach.NUTM1 Gene Fusions Characterize a Subset of Undifferentiated Soft Tissue and Visceral Tumors.BRD4 is a newly characterized transcriptional regulator that represses autophagy and lysosomal function.Emerging roles of transcriptional programs in autophagy regulation.First evidence of treatment efficacy in metastatic carcinoma of the parotid gland with BRD4/NUT translocation.NUT carcinoma presenting in the palate - a case report.Histone deacetylase inhibitor for NUT midline carcinoma.Discovery of BET bromodomain inhibitors and their role in target validationNUT carcinoma of the sinonasal tract infiltrating the orbit in a man with birdshot chorioretinitis.
P2860
Q24310431-8579CC7F-3572-40A0-A13C-1B757C8D5273Q27674710-1231271B-AB04-4870-A98D-8596C8336A6AQ27675927-7E4BFD40-C988-4F48-99E3-95ADC313CE18Q27679878-EAA7B124-9EFD-4A5B-9D3F-D75473FFE47CQ29617196-44BA8E4A-0322-4619-8183-DB2ACC57D8EEQ33732734-2407D86A-5E1C-4718-BB45-EFEF143BB680Q33767688-C38D677E-C0B1-487C-BB9F-455526A9E04AQ33768299-98BC40BB-043E-4A5F-9F51-292944A75DBBQ34030901-402EFDE3-AE5A-456A-8E9E-A13916FCB5E8Q34052714-52CCC472-7D12-4C38-994C-8BF6DB8F5F46Q34513460-2D42B6D3-606B-474C-919A-01341E00AA06Q35048960-87B79FD0-A609-4D25-A557-AB22D81CAFEEQ35061484-6A77FFFB-5229-4766-8167-509CF18B6CF5Q35840882-DB95ED3B-DEA8-422C-815A-60E210D984CDQ35900625-EAA50ECE-B3BD-4687-8D52-4E3D2187155AQ36030365-F8DD4F8F-5827-4200-9E6A-7592DFCEA7CFQ36925162-678DC936-177F-43F8-8DC6-04181F23B7FCQ37571931-C4D34E41-3A5C-4B6F-A9CD-A478D7E5B45EQ37586824-86D4FDE8-7103-4499-A197-BD5D0257CE51Q37940197-18950310-E89E-4620-B303-B3A8E9E33A51Q37950258-D077EC71-5E35-432E-86F2-80F6CEEDEA70Q38126406-A5847054-338E-4909-871D-B7904BE1361AQ38213782-FDBC8D55-4938-4990-9C80-A6B5B441BFCAQ38822314-A3A417A5-1574-45CF-B909-78CAC890F17EQ38874970-09CE6DE2-1022-4910-B2A1-B2DE6104D6F4Q39024306-2B5F90FD-D11C-47CE-824A-DFB10F6BA63BQ39031667-677A2265-1C98-43F6-A06B-D1D6A3FC81EFQ39051416-D4DF8E37-F625-4B11-99A0-5450B89FBA13Q39141456-7987F352-0439-474E-9F15-64237ABFA498Q39663980-B222C320-8696-45D1-B20B-D6C448087F72Q42510502-2BCC0C5A-032D-4666-B55A-EEB47E991800Q46525980-159EF9FD-87E0-4F9B-B3FC-E5B2D1905858Q47847745-B9EF07EA-0E50-48F4-A25D-7C828E9C6C50Q48181245-037F67F7-49DB-4BCA-8E2E-6A5D70B2E700Q48239259-AD23FA72-BD8F-49F5-B280-0AF46B5BF4B4Q49135451-20324977-DA57-4E80-9411-EA22BE64E0C8Q50980220-D44ADF6A-CF13-4B89-9B39-267244C07F27Q51065495-6B6A0897-E3E6-4D41-9501-746FEEA7306DQ54933470-DC2B7DEB-0AB0-4B0C-9D49-823F3A6E6B26Q54956773-15ED46D6-F63E-4B03-B002-475E90CFA926
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
NUT midline carcinoma
@ast
NUT midline carcinoma
@en
NUT midline carcinoma
@nl
type
label
NUT midline carcinoma
@ast
NUT midline carcinoma
@en
NUT midline carcinoma
@nl
prefLabel
NUT midline carcinoma
@ast
NUT midline carcinoma
@en
NUT midline carcinoma
@nl
P2860
P1476
NUT midline carcinoma
@en
P2093
Christopher Alexander French
P2860
P356
10.1016/J.CANCERGENCYTO.2010.06.007
P407
P577
2010-11-01T00:00:00Z